Alvotech Reveals Positive Data For Stelara Rival
Results For AVT04 Ustekinumab Biosimilar Come Ahead Of Oaktree SPAC Merger Vote
Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.
You may also be interested in...
Alvotech and Stada have indicated that they could receive an EMA opinion on their AVT04 Stelara biosimilar as early as the second half of 2023, after the agency confirmed acceptance of their ustekinumab filing.
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.